2021 Q1 Form 10-Q Financial Statement
#000156459021027619 Filed on May 13, 2021
Income Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $8.360M | $8.320M |
| YoY Change | 0.48% | 58.48% |
| % of Gross Profit | ||
| Research & Development | $18.53M | $18.27M |
| YoY Change | 1.42% | 46.79% |
| % of Gross Profit | ||
| Depreciation & Amortization | $291.0K | $283.0K |
| YoY Change | 2.83% | 48.95% |
| % of Gross Profit | ||
| Operating Expenses | $26.88M | $26.59M |
| YoY Change | 1.11% | 50.23% |
| Operating Profit | -$26.88M | -$26.59M |
| YoY Change | 1.11% | 50.22% |
| Interest Expense | -$20.00K | $620.0K |
| YoY Change | -103.23% | 3.33% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$15.00K | $616.0K |
| YoY Change | -102.44% | 3.18% |
| Pretax Income | -$26.90M | -$25.97M |
| YoY Change | 3.58% | 51.87% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$26.90M | -$25.97M |
| YoY Change | 3.57% | 51.86% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$646.3K | -$771.3K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 41.62M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $233.0M | $257.7M |
| YoY Change | -9.58% | 137.51% |
| Cash & Equivalents | $233.0M | $257.7M |
| Short-Term Investments | ||
| Other Short-Term Assets | $387.0K | $966.0K |
| YoY Change | -59.94% | 103.37% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $242.1M | $265.3M |
| YoY Change | -8.74% | 133.38% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $2.930M | $3.400M |
| YoY Change | -13.82% | 18.72% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $900.0K | $1.000M |
| YoY Change | -10.0% | 21.21% |
| Total Long-Term Assets | $3.800M | $4.400M |
| YoY Change | -13.64% | 19.27% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $242.1M | $265.3M |
| Total Long-Term Assets | $3.800M | $4.400M |
| Total Assets | $245.9M | $269.7M |
| YoY Change | -8.82% | 129.79% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $2.700M | $2.100M |
| YoY Change | 28.57% | -39.27% |
| Accrued Expenses | $9.822M | $1.900M |
| YoY Change | 416.95% | -70.67% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $12.80M | $12.80M |
| YoY Change | 0.0% | 28.84% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $200.0K | $400.0K |
| YoY Change | -50.0% | -33.33% |
| Total Long-Term Liabilities | $200.0K | $400.0K |
| YoY Change | -50.0% | -33.33% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $12.80M | $12.80M |
| Total Long-Term Liabilities | $200.0K | $400.0K |
| Total Liabilities | $13.00M | $13.20M |
| YoY Change | -1.52% | 24.76% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$291.3M | |
| YoY Change | ||
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $232.9M | $256.5M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $245.9M | $269.7M |
| YoY Change | -8.82% | 129.79% |
Cashflow Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$26.90M | -$25.97M |
| YoY Change | 3.57% | 51.86% |
| Depreciation, Depletion And Amortization | $291.0K | $283.0K |
| YoY Change | 2.83% | 48.95% |
| Cash From Operating Activities | -$27.34M | -$22.43M |
| YoY Change | 21.86% | 26.47% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $115.0K | $577.0K |
| YoY Change | -80.07% | 69.71% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | ||
| YoY Change | ||
| Cash From Investing Activities | -$115.0K | -$577.0K |
| YoY Change | -80.07% | 69.71% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $93.63M | |
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 799.0K | 93.66M |
| YoY Change | -99.15% | 37067.86% |
| NET CHANGE | ||
| Cash From Operating Activities | -27.34M | -22.43M |
| Cash From Investing Activities | -115.0K | -577.0K |
| Cash From Financing Activities | 799.0K | 93.66M |
| Net Change In Cash | -26.66M | 70.65M |
| YoY Change | -137.73% | -496.34% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$27.34M | -$22.43M |
| Capital Expenditures | $115.0K | $577.0K |
| Free Cash Flow | -$27.45M | -$23.01M |
| YoY Change | 19.31% | 27.29% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y7M24D | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y4M9D | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P6Y8M4D | |
| CY2020Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-26589000 | |
| CY2021Q1 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
25000 | |
| CY2021Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-15000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-26899000 | |
| CY2021Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-26899000 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.65 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.77 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
41618000 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
33667000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
254344000 | |
| CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4635000 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
850000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-26899000 | |
| CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
232930000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
186013000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2822000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
35000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
419000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-25973000 | |
| CY2020Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
616000 | |
| CY2021Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-26884000 | |
| CY2020Q1 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
16000 | |
| CY2020Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-25973000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-25973000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
93628000 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
256525000 | |
| CY2021Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-26899000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-25973000 | |
| CY2021Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
291000 | |
| CY2020Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
283000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4635000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2822000 | |
| CY2021Q1 | avro |
Deferred Rent Expense
DeferredRentExpense
|
-52000 | |
| CY2020Q1 | avro |
Deferred Rent Expense
DeferredRentExpense
|
-53000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1477000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-976000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-10000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-319000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-26000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1443000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-3821000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
635000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-27339000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-22434000 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
115000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
577000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-115000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-577000 | |
| CY2021Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
850000 | |
| CY2020Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
35000 | |
| CY2020Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
93628000 | |
| CY2021Q1 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
-51000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
799000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
93663000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-26655000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
70652000 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
260174000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
187535000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
233519000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
258187000 | |
| CY2021Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
42000 | |
| CY2020Q1 | avro |
Common Stock Offering Costs Incurred But Not Yet Paid
CommonStockOfferingCostsIncurredButNotYetPaid
|
249000 | |
| CY2021Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
233027000 | |
| CY2020Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
257695000 | |
| CY2021Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
492000 | |
| CY2020Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
492000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
233519000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
258187000 | |
| CY2021Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of the Business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO, Inc. (the “Company” or “AVROBIO”) is a clinical-stage gene therapy company focused on developing potentially curative <span style="font-style:italic;">ex vivo</span> lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to clinical-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. <span style="font-size:12pt;"> </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred recurring losses since its inception, including net losses of $26,899 and $25,973 for the three months ended March 31, 2021 and 2020, respectively. In addition, as of March 31, 2021, the Company had an accumulated deficit of $291,315. The Company has primarily funded these losses through the proceeds from sales of common and preferred stock. Although the Company has incurred recurring losses and expects to continue to incur losses for the foreseeable future, the Company expects that its existing cash and cash equivalents on hand as of March 31, 2021 of $233,027 will be sufficient to fund current planned operations and capital expenditure requirements for at least the next twelve months from the filing date of this Quarterly Report on Form 10-Q with the SEC. However, the future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company’s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.<span style="font-size:12pt;"> </span></p> | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-26899000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-25973000 | |
| CY2021Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-291315000 | |
| CY2021Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
233027000 | |
| CY2021Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2021Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities and expenses and the related disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant estimates relied upon in preparing the unaudited condensed consolidated financial statements include the determination of the fair value of share-based awards issued and the estimation of accrued research and development expenses. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> | |
| CY2021Q1 | avro |
Cost Of Milestone Payment
CostOfMilestonePayment
|
0 | |
| CY2020Q1 | avro |
Cost Of Milestone Payment
CostOfMilestonePayment
|
0 | |
| CY2021Q1 | avro |
Fair Value Input Amount Transfer Between Levels
FairValueInputAmountTransferBetweenLevels
|
0 | |
| CY2021Q1 | avro |
Tax Incentive Refund Current
TaxIncentiveRefundCurrent
|
2739000 | |
| CY2020Q4 | avro |
Tax Incentive Refund Current
TaxIncentiveRefundCurrent
|
2558000 | |
| CY2021Q1 | avro |
Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
|
4297000 | |
| CY2020Q4 | avro |
Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
|
3145000 | |
| CY2021Q1 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
692000 | |
| CY2020Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
973000 | |
| CY2021Q1 | avro |
Prepaid Compensation Benefits
PrepaidCompensationBenefits
|
922000 | |
| CY2020Q4 | avro |
Prepaid Compensation Benefits
PrepaidCompensationBenefits
|
609000 | |
| CY2021Q1 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
387000 | |
| CY2020Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
275000 | |
| CY2021Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
9037000 | |
| CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
7560000 | |
| CY2021Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
5642000 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
5485000 | |
| CY2021Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2712000 | |
| CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2421000 | |
| CY2021Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2930000 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
3064000 | |
| CY2021Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
291000 | |
| CY2020Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
283000 | |
| CY2021Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
492000 | |
| CY2020Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
492000 | |
| CY2021Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3460000 | |
| CY2020Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
6402000 | |
| CY2021Q1 | avro |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
5151000 | |
| CY2020Q4 | avro |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
5847000 | |
| CY2021Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
942000 | |
| CY2020Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1096000 | |
| CY2021Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
269000 | |
| CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
348000 | |
| CY2021Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
9822000 | |
| CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
13693000 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | |
| CY2021Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2020Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2021Q1 | avro |
Undesignated Preferred Stock
UndesignatedPreferredStock
|
10000000 | |
| CY2020Q1 | avro |
Undesignated Preferred Stock
UndesignatedPreferredStock
|
10000000 | |
| CY2021Q1 | avro |
Undesignated Shares Of Preferred Stock Outstanding
UndesignatedSharesOfPreferredStockOutstanding
|
0 | |
| CY2020Q1 | avro |
Undesignated Shares Of Preferred Stock Outstanding
UndesignatedSharesOfPreferredStockOutstanding
|
0 | |
| CY2021Q1 | us-gaap |
Dividends Cash
DividendsCash
|
0 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
2359416 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
15.66 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
196872 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
4.32 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
59043 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
17.88 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
7663046 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
15.45 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
9922000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
2254165 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
12.75 | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
8626000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
1729000 | |
| CY2021Q1 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
14147608 | |
| CY2020Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
12266171 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0063 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0096 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.8067 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.7549 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5559545 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
14.97 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
13511000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
133000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
10.69 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
13.68 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
|
2000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
|
15000 | |
| CY2021Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4635000 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2822000 | |
| CY2021Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
56945000 | |
| CY2021Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P3Y2M23D |
